MSB 3.61% $2.87 mesoblast limited

2023 The Final Countdown, page-1217

  1. 8,079 Posts.
    lightbulb Created with Sketch. 1413
    https://hotcopper.com.au/threads/ann-cynata-announces-ceo-succession-and-board-changes.7454356/

    @JB1975 has told us what he thinks.....


    "I don't think MSB gets FDA approval on 3rd August unless the FDA makes a mistake on science or stats - I think those hoping or expecting are only going to get what they hope for if the FDA is essentially corrupted or doesn't do its job properly. That might happen - but the FDA did do its job properly last time and did resist the political pressure of the ODAC vote.

    MSB hasn't put together enough data in the public domain (and they don't have to put it in the public domain - I'm aware of that - but I'm also aware that it wouldn't hurt them to put enough to show scientific credibility and statistical credibility if they had it to do it anyway - so I'm confident they don't) to demonstrate that the one phase 3 trial in children had consistently potent product uncontaminated by potentially confounding other components. If the FDA is swayed by politics or special pleading - medicines will be the worse for that.

    A lot of holders (of MSB) will cheer if MSB gets approval (for pediatric GvHD) when they don;t have the data to support that - but a lot of folk will turn out to watch the fireworks when the world or their city burns too. They won't connect the consequences as being in the net to their detriment."










    Cynata hit 11c today. Single digits look inevitable.


    Last edited by Pledge: 03/07/23
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$2.87
Change
0.100(3.61%)
Mkt cap ! $3.637B
Open High Low Value Volume
$2.83 $2.88 $2.80 $13.74M 4.814M

Buyers (Bids)

No. Vol. Price($)
2 33159 $2.86
 

Sellers (Offers)

Price($) Vol. No.
$2.87 10010 2
View Market Depth
Last trade - 16.10pm 27/01/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.